AZN.UK

11,042

+0.07%↑

GSK

1,401

-0.32%↓

AZN.UK

11,042

+0.07%↑

GSK

1,401

-0.32%↓

AZN.UK

11,042

+0.07%↑

GSK

1,401

-0.32%↓

AZN.UK

11,042

+0.07%↑

GSK

1,401

-0.32%↓

AZN.UK

11,042

+0.07%↑

GSK

1,401

-0.32%↓

Search

Hikma Pharmaceuticals PLC

Open

SectorGezondheidszorg

1,769 0.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1751

Max

1793

Belangrijke statistieken

By Trading Economics

Inkomsten

133M

Verkoop

1.6B

K/W

Sectorgemiddelde

15.82

34.393

EPS

0.6

Dividendrendement

4.13

Winstmarge

8.537

Werknemers

9,500

EBITDA

288M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+37.01% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.13%

2.54%

Volgende dividenddatum

18 sep 2025

Volgende Ex Dividend datum

14 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-831M

4.3B

Vorige openingsprijs

1768.83

Vorige sluitingsprijs

1769

Nieuwssentiment

By Acuity

39%

61%

125 / 374 Rangschikking in Healthcare

Hikma Pharmaceuticals PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 apr 2025, 08:20 UTC

Marktinformatie

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

Peer Vergelijking

Prijswijziging

Hikma Pharmaceuticals PLC Prognose

Koersdoel

By TipRanks

37.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2,441.5Ā GBXĀ  37.01%

Hoogste 2,650Ā GBX

Laagste 1,942Ā GBX

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hikma Pharmaceuticals PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Sentiment

By Acuity

125 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.